Published in Dig Liver Dis on September 16, 2010
Management of perianal fistulas in Crohn's disease: an up-to-date review. World J Gastroenterol (2015) 0.90
Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy. Ann Gastroenterol (2014) 0.83
Second Korean guidelines for the management of ulcerative colitis. Intest Res (2017) 0.83
Second Korean guidelines for the management of Crohn's disease. Intest Res (2017) 0.82
Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Surgical treatment of perianal fistulizing Crohn's disease: from lay-open to cell-based therapy--an overview. ScientificWorldJournal (2014) 0.80
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol (2015) 0.80
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. Int J Colorectal Dis (2011) 0.79
Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol (2011) 0.78
Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol (2014) 0.77
Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis (2015) 0.77
Select a suitable treatment strategy for Crohn's disease: step-up or top-down. EXCLI J (2014) 0.75
Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. World J Gastroenterol (2014) 0.75
Satisfaction and expectations of patients with inflammatory bowel disease on biologic therapy: a multicenter study. Ann Gastroenterol (2016) 0.75
Inflammatory bowel disease nurse specialists for patients on biological therapies: a nationwide Italian survey. Ann Gastroenterol (2016) 0.75
Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. Dig Dis Sci (2017) 0.75
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med (2011) 6.76
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology (2002) 5.71
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology (2002) 4.20
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet (2008) 3.36
Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology (2012) 3.35
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet (2009) 3.19
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol (2005) 2.90
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc (2007) 2.62
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol (2006) 2.50
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.36
Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A (2009) 2.31
Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 2.22
Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology (2011) 2.21
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol (2007) 2.14
An inter- and intra-laboratory comparison of breath ¹³CO₂analysis. Aliment Pharmacol Ther (2003) 2.03
Randomized controlled trial of botulinum toxin versus laparoscopic heller myotomy for esophageal achalasia. Ann Surg (2004) 1.98
Association of DLG5 R30Q variant with inflammatory bowel disease. Eur J Hum Genet (2005) 1.84
Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology (2013) 1.83
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Prevalence of celiac disease in inflammatory bowel diseases: An IG-IBD multicentre study. Dig Liver Dis (2009) 1.82
Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Hum Mol Genet (2010) 1.81
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.81
Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. Eur J Radiol (2007) 1.77
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease. Gastrointest Endosc (2003) 1.64
Lack of intestinal mucosal toxicity of Triticum monococcum in celiac disease patients. Scand J Gastroenterol (2006) 1.63
Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet (2012) 1.61
Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol (2005) 1.61
Evidence-based appraisal of antireflux fundoplication. Ann Surg (2004) 1.59
Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet (2003) 1.57
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 1.55
A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet (2011) 1.54
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's disease. J Crohns Colitis (2011) 1.52
Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol (2003) 1.51
Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol (2009) 1.50
Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem (2003) 1.50
A prospective, longitudinal study of nonconventional strictureplasty in Crohn's disease. J Am Coll Surg (2004) 1.49
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis. J Clin Gastroenterol (2003) 1.48
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol (2008) 1.47
Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review. J Clin Gastroenterol (2014) 1.46
Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: is it useful in compensated cirrhosis? Dig Liver Dis (2012) 1.46
Prevalence and clinical associations of prolonged prothrombin time in adult untreated coeliac disease. Eur J Gastroenterol Hepatol (2004) 1.45
"Appropriateness" or "prioritization" for GI endoscopic procedures? Gastrointest Endosc (2006) 1.43
The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis (2011) 1.43
Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis (2011) 1.41
Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol (2013) 1.41
Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial. Dig Liver Dis (2011) 1.40
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease. J Crohns Colitis (2012) 1.40
European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis (2008) 1.34
Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet (2013) 1.34
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol (2002) 1.32
Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology (2006) 1.29
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis (2011) 1.29
Aberrant DNA methylation in non-neoplastic gastric mucosa of H. Pylori infected patients and effect of eradication. Am J Gastroenterol (2007) 1.28
Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. Gastroenterology (2007) 1.24
Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica (2009) 1.23
Ileal pouchitis-related arthritis. Semin Arthritis Rheum (2002) 1.23
Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn's disease: a prospective comparative study. Am J Gastroenterol (2003) 1.23
Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer (2002) 1.22
Loss of miR-101 expression promotes Wnt/β-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol (2012) 1.22
Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol (2003) 1.21
Retracted Biologic targeting in the treatment of inflammatory bowel diseases. Biologics (2009) 1.20
Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. Dig Liver Dis (2010) 1.19
Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm Bowel Dis (2009) 1.18
DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's disease. Gastroenterology (2007) 1.18
Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis (2011) 1.17
Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol (2007) 1.15